Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Spinal Cord Glioma Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Extra-adrenal Paraganglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
7
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Refractory Chronic Lymphocytic Leukemia, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
romidepsin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Brain Tumors, Spinal Cord Tumors
Interventions
Temozolomide, Lapatinib
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
6
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma
Interventions
Cediranib Maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Central Nervous System Tumor
Interventions
tozuleristide, Canvas imaging system, Surgical resection of tumor
Drug · Device · Procedure
Lead sponsor
John Yu
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced May 21, 2026, 4:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Glioma, Glioma of Brain, Glioma of Spinal Cord
Interventions
Multilingual Aphasia Examination, Language paradigms + RS fMRI, Language paradigms + RS fMRI + one anatomical sequence
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
66
States / cities
Duarte, California • Los Angeles, California • Madera, California + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced May 21, 2026, 4:58 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Pembrolizumab, Stereotactic Radiation Therapy, Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
Chirag G. Patil
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lonafarnib
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced May 21, 2026, 4:58 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
MK-0752
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced May 21, 2026, 4:58 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Neurofibromatosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 75 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions
ENV-101 (taladegib)
Drug
Lead sponsor
Endeavor Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced May 21, 2026, 4:58 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Interventions
Olutasidenib + TMZ
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
12 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Erlotinib hydrochloride
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
3
States / cities
San Diego, California • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced May 21, 2026, 4:58 PM EDT
Not listed Phase 3 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cisplatin, etoposide, ifosfamide, lomustine, methotrexate, prednisone, vincristine sulfate
Drug
Lead sponsor
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Other
Eligibility
3 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced May 21, 2026, 4:58 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Astrocytoma, Oligodendroglioma, Glioblastoma, Glioma, Anaplastic Glioma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 100 Years
Enrollment
3,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced May 21, 2026, 4:58 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study, dexamethasone
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ispinesib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced May 21, 2026, 4:58 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Glioma of Spinal Cord, Glioma of Brainstem
Interventions
GD2 CAR T cells, Fludarabine, Cyclophosphamide, Rituximab
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2043
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced May 21, 2026, 4:58 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced May 21, 2026, 4:58 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System Neoplasm, Spinal Cord Glioma, World Health Organization (WHO) Grade III Glioma, CNS Tumor, Central Nervous System Tumor
Interventions
ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
Drug · Radiation · Procedure
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years to 21 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
valproic acid
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
15
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced May 21, 2026, 4:58 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced May 21, 2026, 4:58 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Glioma
Interventions
Abemaciclib, Temozolomide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
0 Years to 20 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Orange, California • Palo Alto, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 4:58 PM EDT